Jaguar Health

JAGX · Nasdaq · United States

Share price · JAGX

$0.35-14.29 (-97.59%) 3M

close as of 2026-11-18 · 24h delayed · vol 326K (0.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when JAGX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 22 Sep 2026+1190.6%
  2. 17 Sep 2026-21.3%

    Nothing announced by JAGX that day or the session before.

  3. 15 Sep 2026-29.6%
  4. 8 Sep 2026-30.6%
  5. 14 Aug 2026+17.0%
  6. 23 Jul 2026-22.6%

    Nothing announced by JAGX that day or the session before.

  7. 16 Jul 2026-31.5%

    Nothing announced by JAGX that day or the session before.

  8. 4 May 2026-51.4%
  9. 27 Apr 2026-27.8%
  10. 20 Jan 2026-40.2%

    Nothing announced by JAGX that day or the session before.

Share of unusual movement by asset

For each asset, the share of JAGX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Crofelemer(Mytesi)
Approved
Chloride channel (intestinal epithelium)Small molecule
Short Bowel SyndromeHIV-Associated Diarrhea

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Crofelemer · MytesiPhase 2/3Microvillus Inclusion Disease, Congenital Disorders, Rare Diseases
Est. primary completion 2026-12 · NCT06721871 · CT.gov ↗
What to watch
2027 (1)
March 2027 (1)
Crofelemer · MytesiPhase 2Short Bowel Syndrome, Malabsorption Syndromes, Short Gut Syndrome, Post-Op Complication, Functional Gastrointestinal Disorders
Est. primary completion 2027-03 · NCT06904872 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 July 2024Topline resultCrofelemerPhase 3 OnTarget: primary endpoint not met across all tumor types

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$1.2M$3.3M$6.6M—-$5.3M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$20M$3.9M$10M—$8.8M operating cash flowreport ↗
2025-Q3$3.1M$3.7M$3.5M$9.5M-$4.7M operating cash flowreport ↗
2025-Q2$3.0M$3.3M$2.2M$10M-$6.2M operating cash flowreport ↗
2025-Q1$2.2M$3.7M$5.7M$10M-$7.3M operating cash flowreport ↗
2024-Q3$3.1M$4.0M$13M$9.8M-$6.3M operating cash flowreport ↗
2024-Q2$2.7M$3.6M$16M$9.5M-$8.2M operating cash flowreport ↗
2024-Q1$2.4M$4.3M$12M$9.2M-$7.0M operating cash flowreport ↗
2023-Q3$2.8M$6.1M$3.2M$7.8M-$6.8M operating cash flowreport ↗
2023-Q2—$4.3M$8.6M$12M-$9.1M operating cash flowreport ↗
2023-Q1—$4.8M$14M$12M-$9.9M operating cash flowreport ↗
2022-Q3—$5.9M$11M$13M-$8.5M operating cash flowreport ↗
2022-Q2—$2.5M$9.0M$9.4M-$10M operating cash flowreport ↗
2022-Q1—$5.0M$17M$18M-$7.7M operating cash flowreport ↗
2021-Q3—$3.3M$12M$12M-$9.4M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$12M$25M$7.8M$13M-$24M operating cash flowreport ↗

Jaguar Health reported FY 2025 revenue of $11.51M, down 1.5% YoY, with R&D spend of $24.97M, up 51.0% YoY. Cash and equivalents were $7.83M, and the company recorded a net loss of $53.57M, with a quarterly net burn of $53.58M.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$12M$17M$8.0M$9.6M-$29M operating cash flowreport ↗
2023-FY$9.8M$19M$6.5M$10M-$33M operating cash flowreport ↗
2022-FY$12M$18M$5.5M$12M-$33M operating cash flowreport ↗
2021-FY$4.3M$15M$17M<$0.1M-$35M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2025-12-11MICEK JOHN · directorAward / grant7,377——Form 4
2025-12-11MICEK JOHN · directorAward / grant (derivative)7,377——Form 4
2025-12-11Wolin Jonathan S. · See RemarksAward / grant11,740——Form 4
2025-12-11CONTE LISA A · director, See RemarksAward / grant28,592——Form 4
2025-12-11King Steven R. · See RemarksAward / grant11,740——Form 4
2025-12-11Wolin Jonathan S. · See RemarksAward / grant (derivative)11,740——Form 4
2025-12-11CONTE LISA A · director, See RemarksAward / grant (derivative)28,592——Form 4
2025-12-11King Steven R. · See RemarksAward / grant (derivative)11,740——Form 4